BeOne Medicines receives accelerated FDA approval for sonrotoclax in mantle cell lymphoma
BeOne Medicines announced that the U.S. Food and Drug Administration granted accelerated approval to its BCL2 inhibitor sonrotoclax for treatment of mantle cell lymphoma.
The approval is based on early clinical data showing activity in this rare blood cancer, positioning sonrotoclax as a potential competitor to AbbVie and Roche’s Venclexta.
This decision marks the first regulatory clearance for the next-generation BCL2 inhibitor and opens the path for BeOne to pursue additional indications in other blood cancers.
Investors and analysts view the milestone as a significant step for BeOne, potentially expanding its market presence in the oncology sector.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that